Placeholder Banner

PASTEUR Act is Promising Bipartisan Reform, Will Strengthen Antimicrobial Development

June 16, 2021
Media Contact
Vicky Stinson

Today, Congress introduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, which proposes a new approach to drive increased private sector investment & improve financial stability in the market for antibiotic research and development.

The bill was introduced in the U.S. Senate by Senators Michael Bennet (D-CO) and Todd Young (R-IN) and in the U.S. House by Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA).

Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the bill’s introduction:

"Antimicrobial resistance is an urgent public health threat in the United States and around the world. For years, we have seen the number of drug-resistant infections rise while the number of new antibiotics available to fight them drop. Today, Congress has taken an important first step to address this crisis and present a critical public health tool that will help save lives and bring novel innovations to patients.

“I commend U.S. lawmakers for their leadership in taking an important step forward to help tackle this global public health challenge. BIO looks forward to working with lawmakers to continue to strengthen this legislation and other promising bipartisan reforms that will help deliver more innovative antimicrobial medicines to patients.”


Discover More
In an effort to secure medical supply chains and invest in the cures and treatment of the future, members of the House Ways and Means committee this week reintroduced major legislation that "ensures a healthier future for all Americans." BIO…
I AM BIO Podcast’s Spring 2022 Season Explores Water Conservation, Vaccine Technology, Alzheimer’s, and Addiction
John Murphy, Chief Policy Officer at the Biotechnology Innovation Organization (BIO), released the following statement regarding reports of a proposed deal on a Covid-19 vaccine intellectual property rights waiver: “While we have seen the reported…